Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Trichomonas vaginalis including relevant resistance-associated mutations in a single center in the Netherlands
暂无分享,去创建一个
[1] F. V. Aar,et al. Sexually transmitted infections in the Netherlands in 2019 , 2020 .
[2] S. Bruisten,et al. Simultaneous Detection of Neisseria gonorrhoeae and Fluoroquinolone Resistance Mutations to Enable Rapid Prescription of Oral Antibiotics , 2020, Sexually transmitted diseases.
[3] S. Pereyre,et al. Clinical Evaluation of Three Commercial PCR Assays for the Detection of Macrolide Resistance in Mycoplasma genitalium , 2019, Journal of Clinical Microbiology.
[4] X. Beristain,et al. Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014–2017 , 2019, Emerging infectious diseases.
[5] M. Rayment,et al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018) , 2019, International journal of STD & AIDS.
[6] F. Hagen,et al. Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014–2017 , 2019, Emerging infectious diseases.
[7] M. Unemo,et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[8] S. Pereyre,et al. French Prospective Clinical Evaluation of the Aptima Mycoplasma genitalium CE-IVD Assay and Macrolide Resistance Detection Using Three Distinct Assays , 2017, Journal of Clinical Microbiology.
[9] N. Low,et al. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae , 2017, Expert review of molecular diagnostics.
[10] F. Hagen,et al. High prevalence of the A2058T macrolide resistance-associated mutation in Mycoplasma genitalium strains from the Netherlands , 2017, The Journal of antimicrobial chemotherapy.
[11] C. Henquet,et al. Multidrug-resistant Mycoplasma genitalium infections in Europe , 2017, European Journal of Clinical Microbiology & Infectious Diseases.
[12] J. Veerbeek,et al. Routine testing of Mycoplasma genitalium and Trichomonas vaginalis , 2017, Infectious diseases.
[13] M. Cusini,et al. 2016 European guideline on Mycoplasma genitalium infections , 2016, Journal of the European Academy of Dermatology and Venereology.
[14] J. Rahamat-Langendoen,et al. Large two-centre study into the prevalence of Mycoplasma genitalium and Trichomonas vaginalis in the Netherlands , 2016, International journal of STD & AIDS.
[15] M. Cusini,et al. European guideline on Mycoplasma genitalium infections , 2016 .
[16] S. Bruisten,et al. Trichomonas vaginalis and Mycoplasma genitalium: age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands , 2015, Sexually Transmitted Infections.
[17] A. V. van Zwet,et al. High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment. , 2015, The Journal of antimicrobial chemotherapy.
[18] M. Brouwers,et al. Specific andSensitive Detection of Neisseria gonorrhoeae in ClinicalSpecimens by Real-Time PCR , 2005, Journal of Clinical Microbiology.
[19] J. Jensen,et al. Use of TaqMan 5′ Nuclease Real-Time PCR for Quantitative Detection of Mycoplasma genitalium DNA in Males with and without Urethritis Who Were Attendees at a Sexually Transmitted Disease Clinic , 2004, Journal of Clinical Microbiology.